Pfizer Ventures Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 6
- Investments
- 167
- Portfolio
- 51
- Exits
- 83
Pfizer Ventures General Information
Description
Founded in 2004, Pfizer Ventures is the corporate venture capital arm of Pfizer Inc. based in New York, New York. The firm seeks to invest in emerging companies that are developing transformative medicines and technologies. The firm focuses on early-stage opportunities including start-ups and also spinouts.
Contact Information
Website
www.pfizerventures.com
Year Founded
2004
Investor Status
Actively Seeking New Investments
Trade Association
National Venture Capital Association (NVCA)
Primary Investor Type
Corporate Venture Capital
Primary Office
- 235 East 42nd Street
- New York, NY 10017
- United States
+1 (212) 000-0000
Pfizer Ventures Investments (167)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| TRexBio | 08-Mar-2022 | Early Stage VC | 0000 | Drug Discovery | Startup | 000000 0000000 00.0 |
| 000000000 0000000 | 01-Mar-2022 | 00000 00000 | 0000 | Biotechnology | Generating Revenue | 0000 00-000000 00.0 |
| 000000 00000000000 | 11-Feb-2022 | 00000 00000 | 0000 | Drug Discovery | Startup | 00000000000 0'0000000 00.0 |
| 000000 00000000000 | 25-Jan-2022 | 00000 00000 | 0000 | Drug Discovery | Generating Revenue | 00000000000 0'0000000 00.0 |
| 0000000 | 23-Dec-2021 | 00000 00000 | 00000 | Drug Discovery | Generating Revenue | 00000 0000000 00.0 |
| 00000 000000000 | 17-Nov-2021 | 00000 00000 | 00000 | Decision/Risk Analysis | Generating Revenue | |
| 00000 000000000000 | 08-Nov-2021 | 0000 | 000.00 | Drug Discovery | Clinical Trials - Phase 1 | 0000 00-000000 00.0 |
| 000000 00000000000 | 13-Oct-2021 | 00000 00000 | 0000 | Drug Delivery | Generating Revenue | 0000 00-000000 00.0 |
| Anjarium Biosciences | 16-Sep-2021 | Later Stage VC | 000.00 | Drug Delivery | Generating Revenue | |
| eFFECTOR Therapeutics | 26-Aug-2021 | PIPE | 0000 | Drug Discovery | Profitable | 00000 0000000 00.0 |
Pfizer Ventures Exits (83)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Cydan | 31-Dec-2021 | Out of Business | |
| 0000 | 01-Nov-2021 | 000000 0000000000 | 00000 |
| 00000 00000000 | 08-Oct-2021 | 000 | 00000 |
| 0-000 000000000000 | 15-Jul-2021 | 0000000000 | |
| 00000000 | 01-Jul-2021 | 000000000 00000000 | |
| 0000 000000000000 | 16-May-2021 | 000000000000000000 | 000.00 |
| 000000000 | 09-Apr-2021 | 000 | 00000 |
| 000000 00000000000 | 01-Apr-2021 | 000000000 00000000 | |
| Bolt Biotherapeutics | 05-Feb-2021 | IPO | 00000 |
| Epic Sciences | 01-Feb-2021 | Secondary Transaction - Private |
Pfizer Ventures Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialPfizer Ventures Team (11)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Denis Patrick Ph.D | Managing Partner & Vice President, WRDM | 0 | 0 | New York, NY | |
| Barbara Dalton Ph.D | Vice President, WWBD & Senior Managing Partner | 00 | 0 | 0 | New York, NY |
| Christopher O'Donnell Ph.D | Partner & Executive Director, WRDM | 0 | 0 | New York, NY | |
| Michael Baran Ph.D | Partner & Executive Director, WRDM | 0 | 0 | New York, NY | |
| Rana Al-Hallaq Ph.D | Partner & Senior Director, WWBD | 0 | 0 | New York, NY |
Pfizer Ventures Co-Investors (247)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| Alexandria Venture Investments | 12 | 0 | 00 |
|
|
| AbbVie Ventures | 0 | 0 |
|
|
|
| Citadel (Hedge Fund) | 0 | 0 | 0 |
|
|
| RA Capital Management | 0 | 0 |
|
|
|
| HBM Healthcare Investments | 0 | 0 | 0 |
|
|